On June 2, 2021 Aptamer Group Limited, the developer of Optimer Therapeutics, and PinotBio (Gyeonggi-do, Korea), a clinical-stage oncology-focused biotechnology company, reported that they have entered into a strategic collaboration agreement (Press release, Pinotbio, JUN 2, 2021, View Source [SID1234583434]). The agreement is to develop Optimer-drug conjugates for targeted drug delivery combining Aptamer Group’s Optimer technology with PinotBio’s technology using the chemotherapeutic FL-118 compound with specific linker.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Optimer therapeutics are optimized aptamer solutions. Optimer-drug conjugates offer uniquely specific targeting vehicles for the delivery of therapeutic agents to selected cell populations and tissues for the treatment of disease.
Related Stories
Aptamer Group and AstraZeneca to develop new drug delivery vehicles
Aptamer Group and Mologic enter commercial partnership to develop aptamer-based SARS-CoV-2 rapid antigen test
Aptamer Group collaborates with world-leading pharmaceutical company to evaluate Optimer technology
PinotBio’s FL-118 payload system is a novel camptothecin based payload to be used in various carrier-drug conjugates, including Optimer-Drug conjugate. FL-118 shows strong anti-cancer effects against various tumor models and at the same time possesses good safety profiles to be developed as a part of the multi-target collaboration.
Aptamer will provide the developed Optimers to PinotBio for use with their payload and linker technologies. PinotBio will generate and optimize Optimer-drug conjugates against multiple undisclosed targets. Pinotbio will carry out pre-clinical research and development to evaluate each of the Optimer-drug conjugates and their potential to progress as clinical candidates for the treatment of haematological cancers, such as leukaemia, lymphoma, and myeloma.